Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 5, 2001, Pages 450-453

  Ribera, Esteban ^a,b   Pou, Leonor ^a   Lopez, Rosa M ^a   Crespo, Manuel ^a   Falco, Vicenç ^a   Ocaña, Imma ^a   Ruiz, Isabel ^a   Pahissa, Albert ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HIV infection; Nevirapine; Pharmacokinetic interaction; Rifampicin; Tuberculosis

Indexed keywords

NEVIRAPINE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STEADY STATE; TUBERCULOSIS;

EID: 0035894302     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200112150-00007     Document Type: Article

References (12)

1. The treatment of tuberculosis in HIV-infected persons
2. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
3. Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography
4. Stability of rifampin in plasma: Consequences for therapeutic monitoring and pharmacokinetic studies
5. Pharmacokinetic interaction between rifampin and efavirenz in patients with tuberculosis and HIV infection
6. Characterization of the in vitro biotransformation af the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450
7. In vivo modulation of CYP enzymes by quinidine and rifampin
8. Pharmacokinetic interaction between nevirapine and rifampicin
9. Effect of tuberculosis on nevirapine trough plasma concentrations
10. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
11. Variability in activity of hepatic CYP3A4 in patients infected with HIV
12. High-dose nevirapine: Safety, pharmacokinetics and antiviral effect in patients with immunodeficiency virus infection